12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/kZMQ0UsimB

• Predictors of clinical features in early‐onset severe systemic sclerosis: An an…

From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX

• https://x.com/MartinezZayasMd/status/1982137562098487537/photo/1

🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow
• https://x.com/DrMiniDey/status/1982143397759467619/photo/1

Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl

• https://x.com/MartinezZayasMd/status/1982147567065371058/photo/1

Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD

FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb

• FDA Approves Third-Ever Drug for Lupus Nephritis

Great to be with team @RheumNow reporting on the latest from #ACR25 https://t.co/h941qYSc6U

• https://twitter.com/yuz6yusof/status/1981813842545131535

Casal Moura, M., Merkel, P.A., Jayne, D. et al.Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis. Nat Rev Rheumatol (2025). https://t.co/fGUr2DnfwA Good figure, citation above. Via @AKronbichler and colleagues https://t.co/FGfPFiGgMv

• https://doi.org/10.1038/s41584-025-01306-w
• https://twitter.com/illiasulk/status/1981608486208507961

Clinical and Genetic Effects of Neuropsychiatric Lupus The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system. https://t.co/7Ujo6Kaf1N

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/qa9RzmNFU4 https://t.co/dCEkelJzni

• https://buff.ly/8NDmyCc

Colchicine Ineffective in Long COVID Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory https://t.co/9E3dvUFqJP

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/O4Pi8GyT32